|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0019721,
umls-concept:C0063695,
umls-concept:C0086418,
umls-concept:C0123759,
umls-concept:C0185117,
umls-concept:C0441655,
umls-concept:C0441712,
umls-concept:C0456387,
umls-concept:C1513095,
umls-concept:C2911684
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1999-7-8
|
|
pubmed:abstractText |
IL-12 enhances cytolytic activity and proliferation of NK and T cells, and induces cytokines such as IFN-gamma. No direct effects on non-hematopoietic cells have been shown. This study investigates the effects of IL-12 on melanoma cells in vitro. We analyzed 15 melanoma cell cultures and 1 melanoma cell line. Out of 16 samples 13 expressed the beta chain of the IL-12 receptor (IL-12Rbeta). Preincubation with IL-12 increased the surface levels of human leukocyte antigen (HLA) class I, HLA class II and intercellular adhesion molecule (ICAM)-1 of those cultures with IL-12Rbeta expression. The effects of IL-12 on HLA class I could be blocked by an IL-12-neutralizing monoclonal antibody (mAb), but not by an mAb against IFN-gamma. Melanoma cells transduced with IL-12 expressed enhanced levels of HLA class I, HLA class II and ICAM-1 compared to controls. Co-incubation of the melanoma cells with allogeneic peripheral blood mononuclear cells (PBMC) resulted in enhanced proliferation and increased production of IL-2 and IFN-gamma after pretreatment with IL-12. IL-12 pretreatment increased the susceptibility of melanoma cells to lysis by prestimulated autologous PBMC. Since IL-12 induced immunocritical surface molecules on melanoma cells, it might be beneficial during immune interventions in melanoma patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD80,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-D Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/Isoantigens,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-12
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0014-2980
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1762-73
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:10382738-Antibodies, Monoclonal,
pubmed-meshheading:10382738-Antigens, CD80,
pubmed-meshheading:10382738-Antineoplastic Agents,
pubmed-meshheading:10382738-Autoantigens,
pubmed-meshheading:10382738-Genetic Vectors,
pubmed-meshheading:10382738-HLA Antigens,
pubmed-meshheading:10382738-HLA-D Antigens,
pubmed-meshheading:10382738-Histocompatibility Antigens Class I,
pubmed-meshheading:10382738-Humans,
pubmed-meshheading:10382738-Immunotherapy,
pubmed-meshheading:10382738-Intercellular Adhesion Molecule-1,
pubmed-meshheading:10382738-Interferon-gamma,
pubmed-meshheading:10382738-Interleukin-12,
pubmed-meshheading:10382738-Isoantigens,
pubmed-meshheading:10382738-Lymphocyte Activation,
pubmed-meshheading:10382738-Melanoma,
pubmed-meshheading:10382738-Neutralization Tests,
pubmed-meshheading:10382738-Receptors, Interleukin,
pubmed-meshheading:10382738-Receptors, Interleukin-12,
pubmed-meshheading:10382738-Tumor Cells, Cultured,
pubmed-meshheading:10382738-Up-Regulation
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
IL-12 directly up-regulates the expression of HLA class I, HLA class II and ICAM-1 on human melanoma cells: a mechanism for its antitumor activity?
|
|
pubmed:affiliation |
Department of Dermatology, University of Zürich Medical School, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
